For laboratory and research use only. Not for human or animal consumption.Research Use Only • Not for human or animal consumption.

How Are Synthetic Peptides Purified? A Guide to Peptide Purification

Synthesis answers whether a sequence can be built. Purification asks a different question entirely — whether one molecular species can be pulled out of the crowd of species that were built alongside it.

A peptide synthesis can succeed and still not produce a peptide. It produces a mixture.

That is not a failure of technique. It is a structural consequence of how the chemistry works. Solid-phase peptide synthesis assembles a chain by repeating one short cycle of reactions once per residue, and it is the dominant manufacturing route for peptides today.[1] Every one of those cycles is an opportunity for a reaction to run to something less than completion, or for a reaction nobody wanted to run at all. What comes off the resin at the end is the intended sequence accompanied by a population of closely related molecules — and no production route, chemical or biological, yields the target species exclusively.[2]

So the next problem is not can we make this peptide. It is the problem that the crude material from a peptide synthesis hands to whoever receives it: can the desired molecular species be separated from the other species produced alongside it?

That is what purification is. This article is about how it is done, why it is harder than it sounds, and — importantly — what it does not accomplish.

A note on scope. What follows describes purification conceptually. It is an educational overview, not a laboratory procedure, and deliberately omits the operational parameters — solvent compositions, gradients, flow rates, temperatures, column dimensions — that any working method would require.

Why Does a Synthetic Peptide Need to Be Purified?

Because the material coming off the resin is a population, not a compound.

The species in that population arise from several independent sources, and a given synthesis will not contain all of them. Which ones appear depends on the sequence, the chemistry chosen and the conditions used. The recognised categories, though, are well characterised.[1]

Chains that are incomplete. If a coupling or a deprotection step does not go to completion in a given cycle, some fraction of the chains do not receive that residue. The result is a deletion sequence — the intended peptide, minus one or more residues from somewhere in the middle. A chain that stops growing altogether gives a truncation product.[1][2]

Chains that received too much. The mirror-image failure. Amino acid reagents used in excess can add a residue that was not called for, producing an insertion sequence.[1]

Chains that are chemically altered. Side chains can oxidise. Protecting groups can survive the step meant to remove them, leaving adducts. Reactive fragments released during cleavage can attach themselves to the peptide. Residues can epimerise, inverting the stereochemistry at a single carbon while changing nothing else about the molecule.[1][2]

Chains that have degraded. Peptides are not indefinitely stable, and several characteristic degradation routes — among them diketopiperazine, pyroglutamate and succinimide formation — generate their own family of related species.[1]

Chains that found each other. Dimeric and higher oligomeric species can form and appear alongside the monomeric target.[1]

1 · CRUDE MIXTURE full-length target deletion / truncation modified species other process-related 2 · SEPARATION mobile phase stationary phase 3 · DETECTOR TRACE AT THE OUTLET collected retention time target-rich material
Fig. 1 Purification as a separation problem. The species that come off the resin travel through the column at different rates and reach the detector at different times. Only the material eluting inside the collection window is kept. The peaks are drawn overlapping deliberately: that is the normal case, not the exception.

What makes this a genuinely hard separation problem is not the number of species. It is their similarity. Many of these impurities differ from the target by a single amino acid, or by a single functional group, which means they also share most of its chemical properties.[2] A deletion sequence missing one small residue is, from the point of view of almost any physical separation, nearly the same molecule as the target. An epimerised peptide has the identical formula, the identical mass and nearly identical chemistry.

What Is Peptide Purification?

Purification is the separation of a desired molecular species from the other components of a mixture. That is the whole definition. It is worth stating plainly because purification is routinely conflated with two neighbouring operations that answer different questions.

Synthesis constructs. Purification separates. Characterization determines.

Three operations, three questions, three kinds of evidence. No one of them substitutes for another.

Synthesis asks: can this sequence be assembled? Its output is material. Purification asks: can the target species be separated from what accompanies it? Its output is enriched material. Characterization asks: what is actually in this container? Its output is not material at all — it is evidence.

Keeping these apart is the single most useful habit a reader of peptide documentation can acquire, and most of the rest of this article is an argument for why.

Why Chromatography Does This Work

Peptide purification is overwhelmingly chromatographic.[2][3] The reason is that chromatography is unusually good at exploiting small differences.

Every chromatographic system has two parts. A stationary phase stays put — typically a packed bed of porous particles carrying a particular surface chemistry. A mobile phase flows through it, carrying the sample along.

Each molecule in the sample is repeatedly distributed between the two. When it is associated with the stationary phase, it is not moving. When it is in the mobile phase, it travels at the speed of the flow. A molecule’s average velocity through the column is therefore set by how much of its time it spends in each state — which depends on how strongly that particular molecule interacts with the stationary phase relative to the mobile phase.[4]

This is the mechanism worth internalising: chromatography does not sort molecules by size or by any single property directly. It converts a difference in affinity into a difference in time. Two species that interact with the system even slightly differently will spend slightly different fractions of their journey immobilised, and will therefore arrive at the far end of the column at different moments. Given a long enough column and enough repetitions of that partitioning, a very small difference in affinity becomes a measurable difference in arrival time.

POSITION INSIDE THE COLUMN AT THE OUTLET t₁ t₂ t₃ outlet first later time interacts weakly — spends more time moving interacts strongly — spends more time held
Fig. 2 Separation is differential migration. Both species enter together. The one that associates more strongly with the stationary phase spends more of its journey stationary, so it covers less ground in the same interval and reaches the outlet later. Note the two axes are different: position on the left, time on the right.

Retention, Selectivity, Resolution

Three terms describe what comes out of that process, and they are worth separating because they fail independently.

Retention is how long a species is held before it emerges. It is reported as a retention time, and it is a property of the molecule and the system together — the same peptide will show a different retention time under different conditions, which is why a retention time on its own identifies nothing.

Selectivity is whether the system distinguishes two species at all. If the target and an impurity happen to interact with a given stationary and mobile phase in the same way, they will travel together no matter how good the equipment is. Selectivity is a property of the chemistry chosen, and choosing it is most of method development.

Resolution is whether two species that are distinguished actually come out cleanly apart. Two peaks can be centred at different times and still overlap substantially, because each species does not arrive as an instant but as a spread-out band. Resolution combines how far apart two peaks are with how broad each one is.

A separation can fail at any of the three. No selectivity means the impurity is invisible to the method. Poor resolution means it is visible but not removable.

Why Reversed-Phase Chromatography Dominates Peptide Work

The mode most frequently used for purifying peptide mixtures is reversed-phase liquid chromatography, which separates species according to their hydrophobic character.[2]

The name is historical. Early chromatography used a polar stationary phase and a less polar mobile phase; reversing that arrangement — a nonpolar stationary phase, a more polar mobile phase — turned out to suit a great many molecules, peptides among them. A peptide in a mostly aqueous mobile phase will associate with a nonpolar surface; making the mobile phase progressively less polar over the course of the run weakens that preference until the peptide releases and travels on.

Two properties make this a good fit for peptide purification.

The first is that hydrophobicity is a composite property. A peptide’s retention reflects contributions from its constituent side chains, so two chains that differ by even one residue generally differ in retention. Those contributions have been measured directly: intrinsic hydrophilicity and hydrophobicity coefficients for the amino acid side chains have been determined from the reversed-phase retention behaviour of designed model peptides.[5] Usefully, that work also establishes the limits of the idea. The same study defines intrinsic coefficients as the values obtained in the absence of nearest-neighbour and conformational effects — an explicit acknowledgement that in a real peptide, neighbouring residues and the chain’s own folding modulate how fully a side chain expresses its character.[5] Sequence influences retention. It does not dictate it.

The second is sensitivity to small structural differences. Reversed-phase stationary phases can distinguish diastereomers — a peptide epimer, for instance, differing from the target only in the configuration of one residue. What they cannot do is separate enantiomers, which are not distinguishable by an achiral stationary phase at all.[2] This is a precise and useful boundary, and it is characteristic of purification generally: every method has a class of difference it is blind to.

Preparative Chromatography Is Not Analytical Chromatography

This distinction does more work than any other in understanding purification, and it is the point at which most general explanations of chromatography stop being relevant.

Analytical chromatography exists to produce information. A small amount of material is injected, the separation is run under conditions chosen to maximise clarity, and the output is a measurement. The sample is consumed. Nobody wanted it back.

Preparative chromatography exists to produce material.[6] The output is not a number but a collected fraction, and the point of the run is to recover as much of the target as possible in as pure a form as possible. That change of purpose changes the physics of the situation, because recovering a useful quantity means loading the column heavily — and heavily loaded columns behave differently from lightly loaded ones.

Under load, bands broaden and distort. Peaks that were baseline-separated at analytical scale begin to overlap. The classic situation in peptide polishing is a ternary one: the target elutes between a group of more weakly retained impurities and a group of more strongly retained ones, and because those impurities are chemically similar to the target, their peaks overlap it on both the leading and the trailing side. Increasing the load makes this worse.[2]

The consequence is that the operator is not choosing between a pure fraction and an impure one. They are choosing where to start and stop collecting from a continuous, partially overlapping signal.

Purity and Recovery Pull Against Each Other

That choice is the central trade-off of preparative purification, and it is worth being precise about it because it is frequently described in a way that suggests purification is simply a matter of trying harder.

Narrow the collection window around the apex of the target peak and the collected material contains proportionally less of the overlapping impurity — higher purity, at the cost of discarding target molecules that eluted in the shoulders. Widen the window and more of the target is recovered, but the impurity that co-elutes at the edges is collected with it. In batch chromatography, it is practically impossible to achieve both high purity and high yield simultaneously; the literature calls this the yield–purity trade-off.[2]

NARROW COLLECTION WINDOW WIDE COLLECTION WINDOW higher purity in the collected fraction; target eluting in the shoulders is discarded more target recovered; more of the overlapping impurity is collected with it time time
Fig. 3 The same separation, the same trace, one decision changed. Purity and recovery are not independent knobs; in batch chromatography they are two readings of a single choice about where to start and stop collecting. Deliberately unnumbered — the position of the trade-off depends on the peptide and the method, and no general figure applies.

Two qualifications matter here.

The first is that this trade-off has no universal exchange rate. How much recovery a given increment of purity costs depends on the specific peptide, the specific impurities and how well the method separates them. A well-resolved separation makes the trade-off nearly free; a poorly resolved one makes it punishing. Any figure quoted as a general rule should be treated with suspicion.

The second is that the trade-off is a property of batch chromatography, not a law of nature. Continuous multicolumn processes — countercurrent solvent-gradient methods among them — exist specifically to relax it, by running the separation continuously over more than one column instead of as a single batch.[2] The constraint is real, and it is also engineered around.

What Happens to the Impurities?

Not all of them behave the same way, and the distinction the field draws is a useful one for a reader.

Some impurities are unrelated to the product — leftovers from the process that differ from the peptide substantially. These are comparatively easy to remove, because a method only needs to be crudely selective to separate things that are chemically unalike.

The difficult ones are product-related: the deletion sequences, the epimers, the modified forms. Removing these is a distinct stage — polishing — and it is much more challenging precisely because of their similarity to the target molecule.[2] A separation that easily strips out residual reagents may barely register the presence of a peptide missing one glycine.

When a single mode of chromatography cannot resolve a particular impurity, the standard response is orthogonality: run a second separation that sorts on a different property. Ion-exchange, hydrophilic-interaction and reversed-phase chromatography discriminate by charge, hydrophilicity and hydrophobicity respectively, so species that co-elute in one can separate in another.[2]

A published case makes the principle concrete. A 21-residue synthetic peptide was contaminated with versions of itself carrying acetyl groups on serine side chains — a modification small enough that reversed-phase chromatography alone could not resolve it, and cation-exchange alone could not either. A two-step protocol combining mixed-mode hydrophilic-interaction/cation-exchange chromatography with reversed-phase chromatography did separate them, by exploiting subtle differences in the local environment around each acetylation site.[7] One separation was insufficient. Two, chosen to be sensitive to different things, were enough.

Purification is not purely subtractive.

It can introduce material of its own — peptide counter ions, for instance, may originate in the purification treatment rather than the synthesis.[1]

That point deserves emphasis because it cuts against intuition. It is natural to picture purification as a filter that only ever removes. In practice the reagents used during purification participate in the chemistry of the sample, and what emerges carries traces of the process that produced it. Purification changes a material’s composition; it does not simply reduce it.

Why Some Peptides Are Harder to Purify Than Others

Purification difficulty varies widely, and the variation is not random. Several factors recur.

How similar the impurities are. This is the dominant factor. An impurity differing by one small residue, or by stereochemistry alone, sits closest to the target in almost every property a separation could exploit.[2] A published example of a demanding case is the purification of glucagon, a 29-residue peptide, from its epimer along with several other critical impurities arising from deamidation and racemisation.[2]

Hydrophobic character. Very hydrophobic peptides are not always best served by the reversed-phase surface chemistry used by default; alternatives with different retentive character can suit them better, which makes them a method-development problem rather than a routine one.[2]

Self-association. Peptides that associate with one another generate dimeric and higher oligomeric species, which appear as impurities in their own right and give the separation more to resolve.[1]

Instability. Degradation products form a recognised impurity group distinct from the synthesis by-products, so a peptide prone to those routes brings a second, independent source of related species to the same separation.[1]

There is also a factor that runs the other way, and it is one of the more elegant ideas in the field: purification difficulty can be anticipated during synthesis and designed around. If unreacted chains are chemically capped after each coupling step, they cannot rejoin the synthesis in a later cycle — and if the capping group is chosen to be something the separation can grab onto, the failure sequences become easy to remove. One implementation attaches a fluorous tag to unreacted amines, after which the failure products can be pulled out by fluorous chromatography.[8] The purification problem is easiest to solve when the synthesis was planned with it in mind.

What a Chromatogram Actually Shows

The output of a chromatographic run is a trace: detector signal against time. Peaks appear where material reached the detector. Their positions are retention times, their areas relate to how much material arrived, and the degree to which adjacent peaks are separated is the resolution.

That is genuinely informative. It is also narrower than it looks.

A chromatogram is evidence of chromatographic behaviour. It is not, by itself, a molecular identity test.

The clearest way to see the limit is to ask what a single symmetrical peak licenses you to conclude. It says that under these conditions, material reached the detector in one concentrated band at one time. It does not say that the band contained one species — only that whatever it contained was not separated by this method.

This is not a hypothetical concern. Establishing the purity of a main peak in a pharmaceutical peptide analysis is treated as its own analytical problem, addressed with two-dimensional liquid chromatography coupled to mass spectrometry precisely because a single reversed-phase separation cannot settle it.[9]

The reason those two techniques are combined is the most instructive detail in this whole subject. Each covers the other’s blind spot. Mass spectrometry cannot readily distinguish compounds sharing the same mass-to-charge ratio — isomers, and therefore epimers — which is exactly why such species must be resolved chromatographically instead.[9] And chromatography cannot reveal a co-eluting species of different mass hiding inside a peak, which is exactly what the mass spectrometer detects. Neither instrument is sufficient. The combination is strong because the failure modes do not overlap.

How chromatographic data is turned into a purity figure — what a percentage actually counts, and what it silently omits — is a large enough subject to deserve its own treatment, and the analytical use of HPLC is taken up separately.

Purification Is Not Characterization

Everything above concerns separating molecular species. None of it establishes what those species are.

PURIFICATION Can the target species be separated from the rest? output: enriched material ≠ CHARACTERIZATION What is actually present in this material? output: evidence A SAMPLE CAN BE WELL SEPARATED AND STILL NOT BE IDENTIFIED
Fig. 4 Two operations, two questions. Purification changes what is in the container. Characterization changes what is known about it. A certificate that reports only the first has answered half of the question.

Characterization is the set of measurements that establish what a material contains. Chromatographic methods contribute to it, but they are joined by others — mass spectrometry above all, which measures mass-to-charge ratios and, through fragmentation, can read sequence information directly.[10] Amino acid analysis, spectroscopic methods and content assays each answer questions the others cannot.

The relationship between the two operations is worth stating carefully. Purification improves a material. Characterization describes it. A well-purified material that has not been characterised is a material about which something is expected but nothing is established. And characterization is not a single measurement: identity, purity, stability and suitability for a given experiment are four different properties, and no single instrument reports all four.

Two of those questions — what a purity percentage means, and how identity is actually verified — are the subjects of later articles in this series.

Where Purification Sits in the Workflow

amino acids  →  synthesis  →  crude mixture  →  purification  →  enriched material  →  characterization
assembly       many species     separation       one dominant species    identity · purity · stability

Purification is one stage among several, and its position explains both its importance and its limits. It cannot fix a synthesis that assembled the wrong sequence — it can only enrich whatever was made. It cannot report on what it enriched. And it is not the last step: material that has been separated still has to be characterised, and characterisation may reveal that the enriched species was not the intended one.

Why This Matters for Research Quality

The practical reason to understand any of this is that experimental results are interpreted as though they concern a known material.

When they do not, the interpretation inherits the uncertainty. This is a documented concern rather than a theoretical one: peptide-related impurities have been noted as capable of influencing early functionality studies, with the potential for erroneous conclusions.[1]

The careful version of this claim is worth stating, because the careless version is common. Related species in a preparation do not automatically invalidate an experiment. Plenty of research is done with material of modest purity, entirely appropriately, because the question being asked is not sensitive to the difference. What impurities do is introduce an alternative explanation for whatever was observed — and the strength of that alternative depends on the experiment, the impurity and the magnitude of the effect. The point is not that impure material is useless. It is that knowing what a material contains is part of knowing what a result means.

What Purification Does Not Tell You

A short inventory, because these are routinely collapsed into one another:

Question Answered by Not answered by
Was the target separated? The purification itself —
Is this the intended sequence? Identity methods, mass spectrometry among them Purification; retention time alone
How much of the sample is the target? Quantitative analytical methods The fact that material was purified
Will it stay that way? Stability assessment over time and conditions Any single measurement at one moment
Is it suitable for this experiment? The experiment’s own requirements A purity figure on its own

No single number in the right-hand column of a certificate answers the row below it.

Conclusion

The useful mental model is a sequence of three distinct questions, each with its own kind of answer.

Synthesis asks whether a sequence can be constructed, and produces a mixture. Purification asks whether one species in that mixture can be separated from the others, and produces enriched material — subject to a trade-off between how pure the collected fraction is and how much of the target survives into it. Characterization asks what the enriched material actually contains, and produces evidence.

Reversed-phase chromatography does most of the second job, and it does it by turning small differences in molecular character into differences in arrival time. Its limits are the limits of that idea: species too similar to distinguish travel together, and species that travel together look like one thing.

Which is why the chromatogram — the most recognisable artefact of the whole process, the trace that so often stands in for quality — is the wrong place to stop. It records behaviour, not identity. Reading one properly, and knowing what a peak area does and does not count, is the subject of the next article in this series.

References

  1. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012
  2. De Luca C, Lievore G, Bozza D, Buratti A, Cavazzini A, Ricci A, Macis M, Cabri W, Felletti S, Catani M. Downstream Processing of Therapeutic Peptides by Means of Preparative Liquid Chromatography. Molecules. 2021;26(15):4688. doi:10.3390/molecules26154688
  3. Mant CT, Chen Y, Yan Z, Popa TV, Kovacs JM, Mills JB, Tripet BP, Hodges RS. HPLC analysis and purification of peptides. Methods Mol Biol. 2007;386:3–55. doi:10.1007/978-1-59745-430-8_1
  4. Aguilar MI. HPLC of peptides and proteins: basic theory and methodology. Methods Mol Biol. 2004;251:3–8. doi:10.1385/1-59259-742-4:3
  5. Mant CT, Kovacs JM, Kim HM, Pollock DD, Hodges RS. Intrinsic amino acid side-chain hydrophilicity/hydrophobicity coefficients determined by reversed-phase high-performance liquid chromatography of model peptides: comparison with other hydrophilicity/hydrophobicity scales. Biopolymers. 2009;92(6):573–595. doi:10.1002/bip.21316
  6. Guiochon G. Preparative liquid chromatography. J Chromatogr A. 2002;965(1–2):129–161. doi:10.1016/S0021-9673(01)01471-6
  7. Litowski JR, Semchuk PD, Mant CT, Hodges RS. Hydrophilic interaction/cation-exchange chromatography for the purification of synthetic peptides from closely related impurities: serine side-chain acetylated peptides. J Pept Res. 1999;54(1):1–11. doi:10.1034/j.1399-3011.1999.00066.x
  8. Montanari V, Kumar K. Just add water: a new fluorous capping reagent for facile purification of peptides synthesized on the solid phase. J Am Chem Soc. 2004;126(31):9528–9529. doi:10.1021/ja0479033
  9. Petersson P, Buckenmaier S, Euerby MR, Stoll DR. A strategy for assessing peak purity of pharmaceutical peptides in reversed-phase chromatography methods using two-dimensional liquid chromatography coupled to mass spectrometry. Part I: Selection of columns and mobile phases. J Chromatogr A. 2023;1693:463874. doi:10.1016/j.chroma.2023.463874
  10. Steen H, Mann M. The ABC’s (and XYZ’s) of peptide sequencing. Nat Rev Mol Cell Biol. 2004;5(9):699–711. doi:10.1038/nrm1468

The Dice Journal publishes research-focused content on peptide science. Nothing in this article constitutes medical advice, a therapeutic claim, or guidance on the use of research compounds. Research peptides are laboratory materials intended for research use only and are not approved treatments.

How Are Peptides Synthesized? An Introduction to Solid-Phase Peptide Synthesis

A sequence is a design. Getting from that design to a vial of characterized material takes one three-step cycle, repeated once per amino acid — and a great deal of care about what happens when it doesn’t work perfectly.

A peptide is, on paper, a simple object: a defined sequence of amino acids joined end to end. Writing one down takes seconds. Building one is considerably harder.

The difficulty is not forming a peptide bond. Chemists have been doing that since Emil Fischer and Ernest Fourneau assembled glycylglycine — the first free dipeptide — in 1901; Fischer supplied the field’s vocabulary a year later. The difficulty is forming exactly the bonds you intend, in exactly the order you intend, dozens of times in succession — while every amino acid in the flask carries additional reactive groups that would be perfectly happy to react instead. And then demonstrating, afterward, that the molecule you isolated is the molecule you designed.

The dominant solution to that problem is a technique called solid-phase peptide synthesis (SPPS), introduced by R. Bruce Merrifield in 1963 and recognized with the Nobel Prize in Chemistry in 1984.[1] It is one of those rare methods that changed a field not by making an existing process faster, but by reorganizing it around a single structural insight.

This article walks through that insight and its consequences: how a sequence becomes a resin-bound chain, how that chain becomes a crude mixture, and how that mixture becomes characterized research material. Before going further, it may help to review what peptides are and how their structure relates to their behaviour — this article picks up where that one ends.

What Is Peptide Synthesis?

Peptide synthesis is the controlled chemical construction of a peptide with a predetermined amino acid sequence.

Peptides can also be obtained biologically — extracted from tissue, or produced by engineered bacteria or yeast that transcribe and translate an inserted gene. Both routes remain important, and several commercially significant peptides are made recombinantly or by hybrid routes that combine biological expression with downstream chemical modification. But chemical synthesis offers something biology does not: complete freedom over the sequence.

That freedom matters for research. A ribosome builds from a fixed set of twenty proteinogenic amino acids, all L-configured apart from achiral glycine. A synthetic chemist is not constrained that way. D-amino acids, N-methylated residues, unnatural side chains, fluorophores, isotopic labels, cyclization handles, lipid conjugates — none of these are available to a standard expression system without considerable engineering, and all of them are routine in synthesis. When a research question requires a systematic series of sequence variants, chemical synthesis is usually the only practical way to produce them.

Scale and speed also favour synthesis for shorter chains. For a peptide of a few dozen residues, chemical assembly is typically faster to set up than establishing an expression system, and it avoids the biological contaminants — host cell proteins, endotoxin, viral or prion risk — that come with living production hosts. Peptide-based drugs, of which more than eighty have been approved worldwide, are manufactured by both routes depending on length, modification and volume.[2]

The chemistry underneath is the same reaction throughout: the amine group of one amino acid attacks the carboxyl group of another to form an amide bond — the peptide bond — in what is formally a condensation releasing water. Everything else is control.

Why Solid-Phase Peptide Synthesis Matters

Before 1963, peptides were built in solution. Each amino acid was added in a flask, and after each addition the growing peptide had to be isolated and purified before the next step could begin. Yields eroded. Handling losses compounded. Assembling a chain of even modest length was a research project in itself.

Merrifield’s reorganization: anchor the growing peptide to an insoluble solid, and purification becomes filtration.

The peptide is covalently attached at one end to a small polymer bead — the resin — that does not dissolve in the reaction solvent. Reagents are added in solution. When the reaction is done, the bead is simply washed. Everything soluble drains away; the peptide, tethered to the bead, stays. There is no isolation step, no crystallization, no chromatography between residues. There is a filter.

Two consequences follow, and they explain most of what SPPS looks like in practice.

First, reagents can be used in large excess. In solution chemistry, excess reagent is a purification problem. Anchored to a bead, excess reagent is just something you rinse off. Chemists can therefore drive each coupling step much closer to completion than they could otherwise afford to — which matters enormously when the same step must be repeated dozens of times.

Second, the whole process can be automated. Add, wait, drain, wash, repeat. That is a machine’s job, and it has been since the mid-1960s. Merrifield and Bernd Gutte demonstrated the endpoint of that logic in 1969 by chemically synthesizing ribonuclease A — 124 residues, with catalytic activity.[3] Modern automated synthesizers run the same cycle with far better chemistry.

What a resin actually is

It is worth correcting a common mental image. The resin is not a flat surface with peptides standing on it like bristles on a brush.

Typical SPPS resins are microscopic beads of cross-linked polymer — classically polystyrene lightly cross-linked with divinylbenzene, and increasingly polyethylene-glycol-based materials for demanding sequences. In a suitable solvent the bead swells, sometimes to several times its dry volume, taking up solvent throughout its interior. The chemistry then happens in a solvated gel phase, throughout the three-dimensional polymer network, not on a two-dimensional exterior. The vast majority of attachment sites are inside the bead.

This is why solvent choice is not incidental. A solvent that fails to swell the resin leaves most of the growing chains physically inaccessible to reagents, regardless of how reactive those reagents are. It is also why the field’s ongoing effort to replace hazardous dipolar aprotic solvents such as DMF and NMP with greener alternatives is genuinely difficult chemistry rather than a simple substitution.[4, 5]

Between the resin and the peptide sits a linker: a short chemical connector chosen deliberately. The linker determines the conditions required to release the peptide at the end, and it determines what the peptide’s C-terminus looks like once released — a free acid, an amide, or something else. Choosing the linker is one of the first decisions in designing a synthesis, because it is effectively a decision about the last step.

The Basic SPPS Process

swollen resin + linker Load C-terminus anchored × n — one cycle per residue Deprotect expose N-terminal amine Couple form the peptide bond Wash remove all soluble matter Cleave release from resin Crude peptide a mixture, not one species Purify chromatography Characterize identity and purity
Fig. 1 The whole of SPPS. Assembly is a single three-step cycle run once per residue; everything before it is setup and everything after it is downstream processing. Chains grow throughout the interior of the swollen bead, not on its surface.

Two features of this diagram deserve attention before the details.

The chain is built backwards relative to how peptides are written. By convention, peptide sequences are written N-terminus to C-terminus, and ribosomes build them in that direction. SPPS runs the other way: the C-terminal residue is attached to the resin first, and each new amino acid is added at the N-terminal end. This is not arbitrary — it is the direction that minimizes racemization of the residue being activated at each step.

The cycle is the entire method. A 30-residue peptide is not thirty different reactions; it is one three-step cycle executed twenty-nine times. Everything that makes SPPS powerful and everything that makes it fail comes from that repetition.

A note on scope. The sections below describe this process conceptually. This is an educational overview, not a laboratory protocol, and deliberately omits the operational parameters — reagent quantities, concentrations, times, temperatures — that a working procedure would require.

What Happens During Amino-Acid Coupling?

Coupling is the step that forms the new peptide bond. It is also where the selectivity problem becomes concrete.

Consider what an amino acid actually offers a reaction. Every one has an amine group and a carboxyl group. Many also have reactive side chains: lysine has a second amine, aspartate and glutamate have additional carboxyls, serine and threonine and tyrosine have hydroxyls, cysteine has a thiol. Drop a mixture of unmodified amino acids into a flask with a coupling agent and you will get amide bonds — a great many of them, in essentially every possible arrangement, forming an intractable polymeric mess.

Control is imposed by protecting groups: chemical masks attached to functional groups that must not react, removable later under defined conditions.[6]

In practice, a building block used in SPPS carries at least two layers of protection:

  • A temporary group on the α-amine, removed at the start of every cycle to expose the amine for the next coupling.
  • Permanent — more precisely, semi-permanent — groups on reactive side chains, which stay in place throughout the entire assembly and come off at the end.

The critical requirement is that these two layers be orthogonal: removable by chemically independent conditions, so that stripping the temporary group leaves the permanent ones untouched. Without orthogonality, every deprotection would partially dismantle the side-chain protection, and branching would begin.

Two protection schemes dominate, and they differ in exactly this respect. The older Boc/benzyl strategy removes the temporary group with acid and the side-chain groups with stronger acid — a graduated difference in acid lability rather than orthogonality in the strict sense, which is why it depends on careful control of conditions. The now-standard Fmoc/tBu strategy is built on the base-labile 9-fluorenylmethoxycarbonyl group, which Carpino and Han introduced in 1970 and described in full two years later.[7] It uses a mild base for the temporary deprotection and acid for the final cleavage. Fmoc chemistry’s dominance is largely a matter of those two conditions being genuinely independent — base versus acid — which is orthogonality in the strict sense.

The coupling reaction itself requires activating the incoming amino acid’s carboxyl group, since a plain carboxylic acid is not reactive enough toward an amine under mild conditions. Activation converts it into a species that the resin-bound amine will attack readily. Whole families of reagents exist for this — carbodiimides, uronium and aminium salts, phosphonium reagents, each usually paired with an additive that improves efficiency and suppresses side reactions. The choice is not cosmetic: coupling reagents differ measurably in reaction rate, in how well they handle sterically hindered residues, and in how much they promote loss of stereochemical integrity at the activated residue.[8]

That last point is worth stating plainly. Activation makes the α-carbon of the incoming residue vulnerable to epimerization — conversion from the L to the D configuration. A peptide with a single inverted stereocentre has the correct molecular formula, the correct mass, and potentially quite different behaviour. Some residues, notably cysteine and histidine, are more prone to this than others. Coupling chemistry is chosen partly to keep that risk low.

What Is Deprotection?

Deprotection is the removal of the temporary protecting group from the N-terminal amine of the resin-bound chain, and it opens every cycle.

The logic is straightforward. After a coupling, the newly added residue sits at the end of the chain with its own α-amine still masked. If it were not masked, that amine would have been free during the coupling step, and the incoming amino acids would have reacted with each other and with the chain indiscriminately. Masking it is what makes the addition stop at exactly one residue. Unmasking it is what permits the next one.

So each cycle alternates between two states: the chain end is either capped and inert, or exposed and ready. Deprotection is the switch.

In Fmoc chemistry this step has a useful side effect. The removed protecting group generates a byproduct that absorbs ultraviolet light, and modern synthesizers monitor that absorbance in real time. Because the amount of byproduct released is proportional to the number of chains that were successfully deprotected, the instrument produces a per-cycle readout of how the synthesis is going. A cycle that releases less than expected is a signal — often the first indication that the chain has begun to aggregate and that later residues will be harder to add. Chemists also use colorimetric tests on small resin samples to check for free amine before proceeding.

This matters because SPPS is otherwise a somewhat blind process. The product stays locked to the resin until the very end, so there is no opportunity to isolate and inspect an intermediate. Per-cycle monitoring is most of the visibility available.

Why Is the Peptide Washed Between Steps?

Washing is the least glamorous step in SPPS and arguably the one that makes it work.

After each deprotection and each coupling, the bead is rinsed repeatedly with solvent. What drains away is everything that is not the peptide: excess amino acid, spent coupling reagents, the cleaved protecting group and its byproducts, reaction additives, and dissolved base or acid.

Removing all of it before the next step serves several purposes at once.

It defines the reaction boundary. Each step should be a clean transition from one chemical state to the next. Residual reagent from a previous step means the next reaction begins in an ill-defined mixture, and its outcome becomes correspondingly less predictable.

It prevents carryover. Leftover activated amino acid from cycle n is still an activated amino acid during cycle n + 1. If it reaches a newly deprotected amine, it inserts an extra residue that does not belong in the sequence — producing an insertion impurity that is closely related to the target and therefore difficult to separate later.

It limits side reactions. Many degradation pathways in peptide chemistry are driven by prolonged exposure to acid or base. Removing those reagents promptly keeps exposure short.

And it exploits the resin’s central advantage. Because purification is filtration, washing is cheap. The method can afford to be thorough in a way that solution-phase chemistry cannot.

Why Peptide Synthesis Produces Impurities

A crude peptide straight off the resin is not a single molecular species. It is a mixture in which the target sequence is — in a well-executed synthesis — the dominant component.

This is not a sign of poor technique. It is arithmetic.

Suppose each coupling in a synthesis proceeds to 99% completion. That is a genuinely good coupling. Now run it 100 times: 0.99100 ≈ 0.366. Roughly 37% of chains carry the complete correct sequence, and 63% carry at least one defect — even though every individual step performed excellently. Push the per-step efficiency to 99.9% and the same 100-cycle synthesis retains about 90% correct chains.

100% 75% 50% 25% 0% 0 30 60 90 120 coupling cycles (residues added) 36.6% at 100 cycles 99.9% 99% 98%
Fig. 2 Yields multiply rather than add. Nine-tenths of a percentage point in per-step coupling efficiency — 99.9% against 99% — separates a 90% share of correct chains from a 37% share over 100 cycles; a further point down, at 98%, leaves 13%. Which is why so much of peptide chemistry is preoccupied with driving individual reactions closer to completion.

The specific impurities have names, and they are worth distinguishing:

Deletion sequences. A coupling fails on some fraction of chains, but the subsequent deprotection succeeds, and the next residue attaches. The result is a full-length-minus-one peptide missing an internal residue. These are the most troublesome impurities in peptide chemistry: they differ from the target by a single amino acid, so their chromatographic behaviour is often very close to the target’s.

Truncated sequences. A chain stops growing entirely and remains short. Because these differ substantially from the target, they are generally much easier to separate.

Insertion sequences. An extra residue is incorporated, typically from carryover — the failure mode washing is designed to prevent.

target deletion truncation insertion 8 residues, correct order −1 residue — near-identical stopped and capped — easy to separate +1 residue
Fig. 3 Three ways a chain departs from the design. Deletion and insertion products differ from the target by a single residue and can be hard to resolve chromatographically; truncated chains are chemically distant and separate readily. This is why deliberate capping — converting failures into truncations — is often worth its yield cost.

Side-reaction products. The best-known example in Fmoc chemistry is aspartimide formation, in which an aspartic acid residue cyclizes with the adjacent backbone amide under basic conditions. The resulting five-membered ring can reopen to give the correct peptide, a rearranged β-linked isomer, or a partially epimerized product — several distinct impurities from one underlying reaction. Aspartimide formation is sequence-dependent and remains an active area of methodological work, with backbone-protecting building blocks among the more effective countermeasures.[9, 10]

Modification and degradation products. Oxidation of methionine or cysteine, incomplete removal of side-chain protecting groups, unwanted alkylation during the final acidic cleavage, and hydrolysis of sensitive residues all contribute.

Non-peptide material. Residual scavengers, counterions from the cleavage and purification steps, and water. These are not impurities in the sequence sense, but they occupy mass in the final vial — a distinction that becomes important at the characterization stage.

None of this means the synthesis was done badly. It means the crude product requires purification, and that purification requires analytical methods capable of resolving species that are, by construction, extremely similar to the target.

Why Longer Peptides Are More Difficult to Synthesize

Two distinct effects compound, and it is worth separating them.

The statistical effect is the arithmetic in Fig. 2. More cycles means more opportunities for incomplete reaction, and yields multiply rather than add. This part is predictable from length alone.

The physical effect is not predictable from length, and it is the harder problem. As a chain grows on the resin, it can begin to fold, and neighbouring chains can associate with one another — typically forming β-sheet-like hydrogen-bonded structures within the swollen polymer network. When that happens, the reactive N-terminus becomes physically buried. Reagents cannot reach it. Coupling efficiency drops sharply, sometimes within a single cycle, and often at a specific point in the sequence rather than gradually.

Sequences prone to this behaviour are known in the field as “difficult sequences”, and the label is descriptive rather than dismissive. Stretches rich in hydrophobic residues such as valine, isoleucine and alanine are common offenders; so are sequences with strong β-sheet propensity. The onset is frequently abrupt: a synthesis proceeds cleanly for fifteen residues, then coupling efficiency collapses.[11, 12]

Individual residues contribute their own difficulties independently of length. Proline’s ring constrains the backbone and can promote diketopiperazine formation early in a synthesis. Sterically hindered residues couple slowly. Arginine, cysteine and histidine each carry characteristic side reactions.

The important qualification: length does not impose a hard ceiling. A range of strategies extends what is achievable — backbone-protecting building blocks and pseudoproline dipeptides that chemically disrupt aggregation, alternative resins with better solvation properties, elevated-temperature and microwave-assisted synthesis, and fragment-based approaches in which shorter segments are made separately and joined. Native chemical ligation, introduced by Dawson, Muir, Clark-Lewis and Kent in 1994, allows two unprotected synthetic segments to be joined chemoselectively into a native peptide bond, opening chemical access to proteins well beyond stepwise reach.[13] More recently, automated flow chemistry has produced polypeptide chains up to 164 residues in a single continuous synthesis — including folded, catalytically active enzymes — over hundreds of consecutive reactions.[14]

The accurate statement is not that long peptides cannot be synthesized. It is that difficulty rises non-linearly with length and depends strongly on sequence, and that longer targets require method development rather than simply more cycles of the standard procedure.

What Happens After Synthesis?

Assembly ends with cleavage: the peptide is released from the resin, and in Fmoc chemistry the side-chain protecting groups are removed in the same operation, using an acidic mixture that also contains scavengers to intercept the reactive fragments those groups generate. Get this step wrong and previously clean material can acquire a new set of modification products.

What remains after the resin is filtered off and the peptide isolated is the crude peptide — the full mixture described above, with the target sequence as the major component.

crude peptide  →  purification  →  characterization  →  research material
a mixture         separates species   establishes what it is

Crude peptide is a legitimate research material for some purposes, but for most work it is an intermediate rather than a product. Two things still have to happen: the target must be separated from everything else, and its identity must be established. These are different operations answering different questions, and conflating them is one of the more common errors in reading peptide documentation.

How Researchers Purify Synthetic Peptides

Purification means physically separating molecular species that are present together — and in peptide chemistry, species that are often extraordinarily similar.

The dominant technique is reversed-phase high-performance liquid chromatography (RP-HPLC). The principle is separation by hydrophobicity. The crude mixture is dissolved and pumped through a column packed with a hydrophobic stationary phase, usually silica particles bearing long alkyl chains. A mobile phase carries the sample through, and its composition is varied over the run — starting mostly aqueous, becoming progressively more organic. Peptides adsorb to the stationary phase and release when the mobile phase becomes hydrophobic enough to compete for them.

Because that release point depends on the molecule’s overall hydrophobic character, species that differ even slightly emerge at different times. Fractions are collected as they elute; those containing the target are pooled, the organic solvent is removed, and the material is typically lyophilized to a solid.

This works remarkably well, but it has limits worth understanding. Deletion sequences missing a single residue — particularly a small or polar one — can elute very close to the target. Epimerized products differ only in stereochemistry and may separate poorly or not at all on a standard achiral column. Purification therefore reduces impurities; it does not necessarily eliminate every class of them, and the classes hardest to remove are precisely the ones most similar to the target.

Purification separates molecular species. It does not identify them.

A synthesis that assembled the wrong sequence, or that epimerized a residue, can still yield a beautifully sharp single peak.

Chromatography reports that a sample contains one dominant component eluting at a particular time under particular conditions. It does not report what that component is. Purity and identity are distinct properties, established by different measurements.

How Do Researchers Know They Made the Right Peptide?

Identity answers: is this molecule the intended sequence?
Purity answers: how much of the sample is that molecule, and what else is present?

A material can score well on one and badly on the other. Both are needed.

Mass spectrometry is the primary identity tool. The peptide is ionized and its mass-to-charge ratio measured with high precision. Because every sequence has a calculable exact mass, a measured mass matching the theoretical value is strong evidence that the correct residues are present in the correct number.

Strong evidence, but not proof — and the reason is instructive. Mass constrains composition without fixing the order, and it does not always fix composition either: glycine twice over has the same elemental formula as a single asparagine. Leucine and isoleucine are isomers with identical mass and cannot be distinguished by mass alone; separating them requires specialized fragmentation techniques.[15] Two peptides containing the same residues in different sequences are exactly isobaric. And epimerization changes no atoms at all, so a peptide with a D-residue where an L-residue belongs has precisely the expected mass.

Tandem mass spectrometry (MS/MS) closes much of this gap. Fragmenting the peptide inside the instrument produces a ladder of ions whose mass differences correspond to individual residues, allowing the sequence to be read directly. This is standard practice in proteomics and increasingly common in the characterization of synthetic material.

Chromatographic purity is usually reported as an area percentage: the target peak’s area divided by the total area of all detected peaks, typically with ultraviolet detection near 214 nm, where the peptide bond itself absorbs.

That definition carries two consequences most readers of a certificate of analysis do not account for.

First, it is relative to what the detector sees. Salts, water, residual solvents and counterions do not absorb meaningfully at that wavelength and therefore do not appear in the calculation at all. A material can be 99% pure by HPLC area and still be substantially less than 99% peptide by mass. In practice, lyophilized synthetic peptides commonly contain a significant fraction of non-peptide mass — bound water and counterions carried over from purification, with the amount depending strongly on how many basic residues the sequence contains.

Second, purity by area and peptide content by mass are different measurements requiring different methods. Peptide content is determined by techniques such as quantitative amino acid analysis, quantitative NMR, or elemental analysis — none of which are chromatography.[16] Serious characterization packages report both, alongside water content, counterion content and residual solvents.

Additional methods fill in the remaining gaps: amino acid analysis confirms composition after hydrolysis; chiral analysis detects epimerization; NMR provides structural detail; specialized assays address disulfide connectivity in cysteine-containing peptides, which mass alone cannot resolve.

The full treatment of these methods belongs in their own articles. The distinction to carry forward is this: a single purity number, unqualified, describes one property measured one way. It is useful information. It is not a complete description of a material.

What Can Go Wrong During Peptide Synthesis

A consolidated view of the failure modes discussed above, roughly in the order they arise.

Stage Problem Consequence
Loading Inefficient or uneven attachment of the first residue Reduced yield; heterogeneous starting population
Coupling Incomplete reaction Deletion sequences
Coupling Epimerization at the activated residue Diastereomeric impurity with identical mass
Deprotection Incomplete removal of the temporary group Truncated or deletion products
Deprotection Base-mediated aspartimide formation Multiple rearranged and epimerized species
Washing Reagent carryover Insertion sequences
Elongation On-resin aggregation Abrupt collapse in coupling efficiency
Cleavage Alkylation by released protecting-group fragments Covalently modified peptide
Cleavage Incomplete side-chain deprotection Partially protected peptide
Handling Oxidation of Met or Cys; disulfide scrambling Modified or misfolded product
Purification Co-elution of closely related impurities Residual impurity in “purified” material

Two observations about this table.

Most of these failure modes are anticipated and designed against rather than discovered after the fact. Capping is a good example: after each coupling, remaining unreacted amines can be deliberately and irreversibly blocked. This does not recover the failed chains — but it converts them from deletion sequences, which are hard to separate, into truncated sequences, which are easy. Accepting a small yield loss to make the impurity profile tractable is characteristic of how the field thinks.

And most are sequence-dependent. There is no universal SPPS procedure that is optimal for every target. Method development is a real part of making a peptide, particularly a long or awkward one.

Why Peptide Synthesis Matters for Research Quality

Everything above has a downstream consequence: the material is part of the experiment.

An experiment performed with a peptide measures the behaviour of whatever was actually in the vial. If the sequence is wrong, the result describes a different molecule. If a meaningful fraction of the sample is a deletion product, the effective concentration of the intended peptide is lower than assumed and any dose- or concentration-dependent relationship shifts accordingly. If a fraction is epimerized, the sample contains a stereoisomer that may behave differently. If a substantial share of the mass is water and counterions, a solution prepared by weight is more dilute in peptide than the calculation implies — which is why peptide content, not just purity, appears on rigorous characterization documents.

This connects to reproducibility in a direct way. Two laboratories working from the same published sequence, using material from different sources with different impurity profiles and different peptide content, can obtain different results without either having made a procedural error. The variable was the material. Poorly characterized reagents are a recognized contributor to irreproducibility across the life sciences, and peptides — where similar-looking material can differ in ways that only targeted analysis reveals — are a clear instance of the general problem.

The practical implication is not that researchers should distrust synthetic peptides. It is that characterization data is part of the material, and material without it is harder to interpret. Knowing how a peptide was made, what impurities that process tends to generate, and which analytical methods were applied is what makes a purity figure meaningful rather than decorative.

What We Know — and What Still Has to Be Verified

The chemistry of solid-phase peptide synthesis is exceptionally well established. Sixty years of literature describe the reaction mechanisms, the failure modes, the sequence-dependent difficulties, and the analytical methods used to detect all of the above. This is not a frontier field. It is a mature one, with active methodological development at its edges — greener solvent systems, flow chemistry, improved coupling reagents, aggregation-disrupting building blocks — sitting on a very solid foundation.

What that maturity does not do is transfer automatically to any particular batch of material.

“This peptide can be synthesized” is a statement about chemistry. “This material is the correct peptide, at a defined purity and content” is a statement about a batch.

The first is established by the literature. The second is established only by measurement.

A synthesis route that works reliably says nothing definitive about the vial in front of you; that requires identity confirmation, purity determination, content assay, and — depending on the application — additional testing for stereochemical integrity, disulfide connectivity or residual solvents.

Understanding how peptides are synthesized is ultimately useful for exactly this reason. It tells you which questions to ask about a material, which impurities a given sequence is likely to carry, and why the difference between a chromatogram and a mass spectrum matters. A sequence is a design. A characterized material is a result.

References

  1. Merrifield RB. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. J Am Chem Soc. 1963;85(14):2149–2154. doi:10.1021/ja00897a025
  2. Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022;7:48. doi:10.1038/s41392-022-00904-4
  3. Gutte B, Merrifield RB. The total synthesis of an enzyme with ribonuclease A activity. J Am Chem Soc. 1969;91(2):501–502. doi:10.1021/ja01030a050
  4. Isidro-Llobet A, Kenworthy MN, Mukherjee S, et al. Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production. J Org Chem. 2019;84(8):4615–4628. doi:10.1021/acs.joc.8b03001
  5. Martin V, Egelund PHG, Johansson H, et al. Replacing DMF in solid-phase peptide synthesis: varying the composition of green binary solvent mixtures as a tool to mitigate common side-reactions. Green Chem. 2021;23(9):3312–3321.
  6. Isidro-Llobet A, Álvarez M, Albericio F. Amino Acid-Protecting Groups. Chem Rev. 2009;109(6):2455–2504. doi:10.1021/cr800323s
  7. Carpino LA, Han GY. 9-Fluorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group. J Am Chem Soc. 1970;92(19):5748–5749. doi:10.1021/ja00722a043 — full paper: J Org Chem. 1972;37(22):3404–3409. doi:10.1021/jo00795a005
  8. El-Faham A, Albericio F. Peptide Coupling Reagents, More than a Letter Soup. Chem Rev. 2011;111(11):6557–6602. doi:10.1021/cr100048w
  9. Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4–27. doi:10.1002/psc.2836
  10. Kong X, et al. Aspartimide Formation and Its Prevention in Fmoc Chemistry Solid Phase Peptide Synthesis. ChemBioChem. 2025. doi:10.1002/cbic.202500490
  11. Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat Protoc. 2007;2(12):3247–3256. doi:10.1038/nprot.2007.454
  12. Paradís-Bas M, Tulla-Puche J, Albericio F. The road to the synthesis of “difficult peptides”. Chem Soc Rev. 2016;45(3):631–654. doi:10.1039/c5cs00680e
  13. Dawson PE, Muir TW, Clark-Lewis I, Kent SBH. Synthesis of proteins by native chemical ligation. Science. 1994;266(5186):776–779. doi:10.1126/science.7973629
  14. Hartrampf N, Saebi A, Poskus M, et al. Synthesis of proteins by automated flow chemistry. Science. 2020;368(6494):980–987. doi:10.1126/science.abb2491
  15. Armirotti A, Millo E, Damonte G. How to discriminate between leucine and isoleucine by low energy ESI-TRAP MSn. J Am Soc Mass Spectrom. 2007;18(1):57–63. doi:10.1016/j.jasms.2006.08.011
  16. Purity assignment for peptide certified reference materials by combining qNMR and LC-MS/MS amino acid analysis results: application to angiotensin II. Anal Bioanal Chem. 2018. doi:10.1007/s00216-018-1272-7

The Dice Journal publishes research-focused content on peptide science. Nothing in this article constitutes medical advice, a therapeutic claim, or guidance on the use of research compounds. Research peptides are laboratory materials intended for research use only and are not approved treatments.

What Are Research Peptides? Structure, Synthesis, and How They Are Studied

What a peptide is

The IUPAC-IUB Joint Commission on Biochemical Nomenclature defines a peptide as any compound produced by amide formation between a carboxyl group of one amino acid and an amino group of another. That is the whole definition. A peptide is a chain of amino acids joined by amide bonds, and everything else follows from it.

The individual units in the chain are called residues. The bond between them is an amide bond; when it links the alpha-carboxyl position of one residue to the alpha-amino position of the next, the nomenclature calls it a eupeptide bond, and when it links other positions, an isopeptide bond. The chain has two distinguishable ends. The N-terminal residue is the one whose amino group is free, or at least is not acylated by another amino-acid residue. The C-terminal residue is the one with a free carboxyl group, or which at least does not acylate another residue. Sequence is what makes one peptide a different substance from another.

Nothing in that definition mentions research. The phrase research peptide describes an intended use and a supply context, not a chemical class. A peptide sold for laboratory work and a peptide in a licensed medicine can be the same molecule; what differs is the regulatory framework and the evidence attached to it, which the last two sections of this article deal with directly.

Peptide or protein? A convention, not a rule

The most repeated claim about peptides is that a peptide becomes a protein above fifty amino acids. The nomenclature source is considerably less confident than that.

IUPAC-IUB describes oligopeptides as peptides with fewer than about ten to twenty residues, and states that polypeptides of specific sequence of more than about fifty residues are usually known as proteins. The hedging is in the recommendation itself, not added here. Two separate qualifiers appear in a single sentence, and the band between roughly twenty and fifty residues is left without a name.

That imprecision is not an oversight. There is no chemical discontinuity at any particular residue count: the bond chemistry at residue forty-nine is the same as at residue fifty-one. The nomenclature body is recording how chemists conventionally speak, not legislating a physical boundary. Secondary sources drop the hedging because a single number is easier to repeat than a convention with soft edges, which is how an approximation became a rule that the original text does not support.

How research peptides are made

The dominant method is solid-phase peptide synthesis, introduced by R. B. Merrifield in the Journal of the American Chemical Society in 1963. The idea is to add protected amino acids stepwise to a peptide chain that is held by a covalent bond to a solid resin particle. Because the growing chain is anchored to something insoluble, excess reagents can be washed away between steps.

Modern practice is dominated by Fmoc chemistry. A 2016 review in the Journal of Peptide Science describes Fmoc solid-phase synthesis as having become the dominant peptide synthesis method, supported by very-high-quality Fmoc building blocks available at low cost through economies of scale, and by a broad range of commercially available modified derivatives that make synthetic access to a broad range of peptide derivatives straightforward.

The consequence of a stepwise method matters more than the chemistry itself. Each residue is added in a separate cycle, which is why the manufacturing process is itself one of the recognised sources of impurity in a finished peptide, alongside the starting materials and storage conditions. Deletion and truncation sequences are among the impurity classes that arise.

What is actually in the vial

A peptide preparation is a mixture. A 2021 review in the Journal of the American Society for Mass Spectrometry notes that synthetic peptides are subject to many complex structural modifications originating from three distinct places: the starting materials, the manufacturing process, and storage conditions.

Some of that material is analytically awkward. The same review identifies distinguishing structural isomers and stereoisomers, particularly peptide epimers, as a standing challenge.

The rest of the non-target material is not peptide at all. Purification leaves counterions behind, and a 2023 paper in Pharmaceutical Research on reference standards for synthetic peptide therapeutics accounts separately for acetic acid, trifluoroacetic acid, residual solvents, inorganic residues and water. None of those are impurities in the sense of being wrong molecules. They are simply mass in the vial that is not the peptide.

How purity is measured, and what the number leaves out

A purity figure on a certificate is usually a chromatographic measurement. High-performance liquid chromatography separates the components of a sample and the main peak is compared against the total detected peak area. The resulting percentage is a statement about the proportion of detected material attributable to the target sequence.

That qualifier does most of the work. The Pharmaceutical Research reference-standard paper sets out a mass-balance approach in which, for purity assignment, all species other than the native peptide – impurities and counter ions alike – should be identified and measured. It accounts for counterions, residual solvents, inorganic residues and water content as separate determinations precisely because standard chromatographic purity does not see them. A preparation can be highly pure by peak area and still contain mass that is salt and water.

Identity and quantity are also separate questions from purity, and from each other. The same paper describes identity being confirmed by several methods used together – chromatographic retention time, nuclear magnetic resonance, mass spectrometry and chiral testing – while content is assayed against a calibrated standard once bulk purity has been established. Three different numbers answer three different questions.

Measurement What it answers What it does not answer
Chromatographic purity (peak area) What proportion of chromatographically detected material is the main peak How much counterion, water, residual solvent or inorganic residue is present
Mass spectrometry and orthogonal identity testing Whether the material is the sequence it is claimed to be How much of it there is, and whether epimers or isomers are present without dedicated methods
Content assay against a calibrated standard How much peptide is present by mass Whether the remaining mass has been characterised

Reading a real certificate against those three questions is more informative than reading a single headline percentage. Dice makes its published certificates of analysis available, and the distinctions above are the ones worth applying to them.

Why peptides are chemically fragile

The amide bond that defines a peptide is also a target for enzymes that hydrolyse it. A 2021 study in Clinical and Translational Science, which synthesised a peptide library and measured its stability in serum, describes proteolytic degradation as the primary instability mechanism and notes that it occurs mainly in plasma but also in the gastrointestinal system, the liver and in immune cells.

The measured spread in that library was wide. Half-lives ranged from approximately 7.4 to 403.4 minutes – roughly a fifty-fold difference across peptides made in the same laboratory by the same methods. The authors identified four sequence-related properties that correlated with stability: higher nonpolar residue content and the presence of two or more tyrosine residues were associated with longer half-lives, while the presence of tryptophan and a higher isoelectric point were associated with shorter ones. Their predictive model reported an R-squared of 0.76 to 0.78.

Two limits on that finding should be stated plainly. These are in vitro serum measurements on a library designed to probe the question, not in vivo pharmacokinetics, and they describe the behaviour of that library rather than of any specific commercial peptide. The transferable point is structural rather than numerical: sequence composition materially affects how long a peptide survives in biological fluid.

How peptides are studied

Evidence about a peptide is not one undifferentiated body of knowledge. It arrives in classes, and the class determines what a finding can support. In vitro work observes behaviour in cells or cell-free systems. Animal preclinical work observes it in a living organism that is not a human. Mechanistic work explains how something could act without demonstrating that it does at a given dose in a given species. Observational and non-randomised clinical work describes what happens in people without controlling assignment. Randomised controlled trials control assignment. Systematic reviews and meta-analyses aggregate across studies. A finding does not become stronger by being restated; it becomes stronger by being reproduced in a class of evidence that can carry more weight.

The distance between those classes has been measured. A 2024 analysis in PLoS Biology examined 122 systematic reviews covering 367 therapeutic interventions across 54 human diseases and reported that 50% of interventions progressed from animal studies to any human study, 40% reached randomised controlled trials, and 5% obtained regulatory approval. Median transition times were five years to human studies, seven to randomised trials, and ten to approval.

None of that means the class is unproductive. The 2021 Nature Reviews Drug Discovery review of peptide drug discovery records that, since the introduction of insulin almost a century ago, more than eighty peptide drugs have reached the market across indications including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain. That figure is a 2021 count.

Where the evidence on translation disagrees

The translation literature does not speak with one voice, and the disagreement is worth seeing rather than resolving artificially.

The same 2024 PLoS Biology analysis that reports a 5% approval rate also reports 86% concordance between positive results in animal and clinical studies, and its authors conclude that animal-to-human translation may be higher than previously reported while the low approval rate still indicates deficiencies in study design and generalisability. Against that, a 2019 systematic scoping review in the Journal of Translational Medicine, covering 121 publications that compared findings across at least two species including humans, found reported translational success rates ranging from 0 to 100%. Its authors judged the included studies to carry a high risk of bias and much of the evidence to be outdated, and concluded that translational success cannot be assumed predictable in advance.

The two are measuring different things rather than contradicting each other outright. Concordance compares matched positive results between an animal study and a human one. An approval rate measures survival through an entire development pipeline in which failure includes toxicity, insufficient effect size and commercial abandonment. The 2019 review also aggregates heterogeneous definitions of success across research fields, which mechanically widens the range it reports. Neither figure has been shown to apply specifically to peptide interventions; the 2024 analysis covers therapeutic interventions across 54 diseases without a peptide-specific breakdown.

What “research use only” actually means

The phrase attached to research peptides has a traceable origin. Under 21 CFR 809.10, in the text current as of 2026, the labelling statement prescribed for a product in the laboratory research phase is “For Research Use Only. Not for use in diagnostic procedures.”

The context of that regulation is specific. Part 809 governs in vitro diagnostic products for human use. That is the framework the familiar wording comes from, and it is narrower than the way the phrase is generally used.

What the statement asserts is therefore limited, and worth stating precisely. It describes an intended use and a labelling obligation. It is not an approval, not a safety finding, not a quality certification, and not a statement that anything has been tested for any effect in a person. A compound labelled for research use has not thereby been shown to do anything; it has been declared to be outside the framework in which such a showing would be required. Nothing in the evidence base assembled for this article establishes a general statutory category covering research peptides outside that in vitro diagnostic context, which is a gap in the public understanding of the term rather than a settled point.

What this article does not tell you

The boundaries of the evidence used here are as important as its contents.

  • No source used in this article audits how often commercially sold research peptides meet their stated purity. The analytical literature establishes what should be measured and why chromatographic purity is incomplete; it does not establish how frequently suppliers get it right.
  • The serum half-life range quoted comes from one designed peptide library measured in vitro. It cannot be transferred to any specific compound, and no in vivo half-life should be inferred from it.
  • The literature cited confirms that deletion, truncation and epimerisation impurities exist and are analytically difficult. It does not establish how often they occur at meaningful levels in routine commercial synthesis.
  • The count of more than eighty approved peptide drugs is a 2021 figure and is treated here as a snapshot rather than a current total.
  • Whether the translation statistics above apply to peptides specifically has not been tested in the sources used.

This article is also deliberately silent on a whole category of question. It contains no dose, no route, no frequency, no reconstitution or storage procedure and no protocol of any kind, because it is written about what researchers have studied rather than about what anyone should do with a compound. Dice supplies materials for laboratory and research use only, not for human or animal consumption, and the definitional scope of this article ends where that boundary begins. Work that examines specific compounds, testing methods and handling chemistry in depth appears across the rest of the Dice Journal.